As the world continues to face chronic pain disorder burden, efficient and relieving topical pain relief becomes paramount for managing this condition. Given this, global demand for topical pain relief is anticipated to surge at a 5.6% CAGR through 2034.
The market value is projected to increase from US$ 11,061.3 million in 2024 to US$ 18,994.4 million by 2034. The market was valued at US$ 10,513.1 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 5.2% in 2024.
| Attributes | Market Insights |
|---|---|
| Base Value, 2023 | US$ 10,513.1 million |
| Global Topical Pain Relief Market Size (2024) | US$ 11,061.3 million |
| Market Forecast for Topical Pain Relief Industry (2034) | US$ 18,994.4 million |
| Value-based CAGR (2024 to 2034) | 5.6% |
Rising aging population is surging the demand for pain management solutions, particularly topical pain relief medications for chronic pain problems such as arthritis, back pain, and muscle pain.
These products offer convenience and relief, making them highly preferred over invasive ones. Continuous research & development efforts by leading manufacturers can improve the effectiveness and safety of these pain relief solutions.
Following the COVID-19 pandemic, people are adopting healthy habits and engaging in sports activities, which are prone to acute injuries. Sprays are used to relax suffering in these sports.
A competitive industry is created by the various topical pain treatment medications offered by pharmaceutical and healthcare companies. Regulatory licenses and safety regulations are essential in the market as they influence product accessibility and customer confidence.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market recorded a historical CAGR of 4.0% from 2019 to 2023. Historically, pain relief medications have been developed through ongoing research and development, focusing on novel formulations, optimizing active component bioavailability, and improving delivery systems.
The incidence of chronic and neuropathic pain rises with age, with adults being more susceptible to these conditions. Chronic and neuropathic pain are increasingly prevalent due to health conditions like diabetes, cancer, and autoimmune diseases. The conditions necessitate healthcare providers to monitor these rates and provide appropriate treatment options.
The growing prevalence of neuropathic and chronic pain is projected to fuel growth of the market, with a focus on non-opioid medications and the development of safer, more effective pain management therapies.
Reimbursement policies by governments are set to encourage healthcare professionals to offer non-opioid topical therapies in palliative care plans.
Consumers seek natural and organic alternatives in healthcare and personal care, leading to the development of topical pain treatment medicines containing natural components. Leading companies and manufacturers are investing in research & development to produce unique formulations for precise and efficient pain treatment.
Technological developments, such as transdermal medication delivery methods, enhance active chemical absorption, providing reliable and long-lasting pain relief.
The market is further projected to grow due to rising geriatric population, high prevalence of chronic diseases, increased sports activity, and accidental injuries. The safety and efficacy of these treatments are projected to push manufacturers to develop unconventional products, such as one-shot technology in sprays, to enhance treatment efficacy.
Principal Consultant
The market is undergoing a shift toward non-opioid alternatives due to increased public awareness of opioid risks and the need for safe alternatives. Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased their sales globally.
According to the International Association for the Study of Pain (IASP), around 20 to 30% of opioids prescribed for chronic pain are being misused. It also mentions that up to 10% of the total opioid consumers are addicted to it. The growing incidence of opioid abuse is set to hinder growth in the market.
The table below highlights the anticipated growth rates of leading countries. Among these, China is projected to remain a highly lucrative market for topical pain relief, exhibiting a CAGR of 8.4%. The United States and India are anticipated to follow with CAGRs of 3.8% and 7.1%, respectively.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 3.8% |
| Germany | 3.1% |
| United Kingdom | 2.6% |
| Japan | 2.4% |
| China | 8.4% |
| India | 7.1% |
Manufacturers in the United States often prioritize natural and organic ingredients in their product formulations to satisfy the increasing demand for wellness-focused, clean-label products. Public education campaigns by NGOs and governments have been running to inform people about the benefits of topical painkillers and how to use them safely & appropriately.
CBD, a potent analgesic and anti-inflammatory, is gaining traction as a natural substitute for pain relief medicines in the United States. This trend is propelled by pharmacies, drugstores, supermarkets, and internet platforms offering topical pain relief solutions, with direct-to-consumer sales channels emerging due to convenience.
China's growth in the topical pain relief market is notable, with a surge in commercial development through novel product approvals. The country's robust investment in research & development, coupled with a burgeoning healthcare sector, has propelled the demand for topical pain relief.
Growing awareness and adoption of topical pain relief products in various applications contribute to China's flourishing market, positioning the country as a key player in the global landscape.
The demand for over-the-counter pain relievers in China is growing due to the rise in arthritis, diabetic neuropathy, and joint pain, as well as the increasing elderly population. Leading companies in China are introducing new pain relief components, delivery systems, and formulations to meet consumer needs.
India is making significant strides in the market. It is projected to showcase positive growth trends by 2034. Chronic pain conditions are on the rise in India due to the growing elderly population and changing lifestyles characterized by more stress & sedentary behavior.
A sizeable section of the populace suffers from conditions such as joint pain, arthritis, and back pain, fueling demand for topical pain relief in India. For instance, millions of Indians have arthritis, with osteoarthritis being the most common type, especially in older adults.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below signifies leading sub-categories under drug class, formulations, and packaging type categories in the market. The non-opioids segment is projected to surge at a CAGR of 4.7% in the evaluation period. Under the formulation category, the cream and ointment segment is projected to rise at a CAGR of 3.0% by 2034.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Tubes (Packaging Type) | 3.3% |
| Hospitals (Distribution Channel) | 7.0% |
| Creams and Ointments (Formulation) | 3.0% |
| Non-opioids (Drug Class) | 4.7% |
The non-opioid segment dominated the global market with a 72.5% share in 2023 and is projected to continue experiencing high growth throughout the forecast period. Topical pain medications without opioids are considered safer due to their lower risk of addiction, dependence, and overdose compared to opioid-based alternatives.
Healthcare professionals prefer non-opioid formulations for the treatment of mild to moderate pain, particularly for chronic conditions that call for long-term use. Compared to oral medications, non-opioid topical pain relievers usually have fewer systemic side effects, fueling the segment’s growth.
Cream formulations are widely utilized in topical pain management because of their rapid skin absorption, simplicity of administration, and capacity to deliver targeted comfort.
Various active ingredients meant to lessen pain and suffering are frequently used in pain relief creams. Manufacturers often carry out clinical trials to demonstrate the efficacy and safety of their cream formulations, further propelling demand.
The tube segment dominated the global market with a 35.7% share in 2023 and is projected to continue experiencing substantial growth by 2034. Since tubes often have a sealed nozzle or cap that helps keep product integrity and avoid contamination, they offer a hygienic application method.
Tubes are also essential for applying topical pain relief medications directly to the affected area, making them easy to use and effective for skin contact. The easy dispensing mechanism of tubes makes the product's smooth and even application possible.
Leading topical pain relief product manufacturers prioritize product innovation and launches to meet high demand and broaden their global consumer base through unique formulations & delivery methods. Manufacturers in the pharmaceutical sector also apply for authorization from regulatory organizations to stay relevant in the market.
For instance
The global market is set to reach US$ 18,994.4 million by 2034.
Demand for topical pain relief is slated to rise at a 5.6% CAGR by 2034.
The non-opioids segment is set to lead the global market in 2024.
The market is projected to reach US$ 11,061.3 million in 2024.
The United States accounted for around 33.5% share of the global market in 2023.
Johnson & Johnson, Pfizer Inc., and Novartis AG are the key players.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Class Innovation / Development Trends
4. Key Success Factors
4.1. Drug Class Adoption/ Usage Analysis
4.2. Regulatory Scenario
4.3. PESTLE Analysis
4.4. Porter’s Analysis
4.5. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Painkillers Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rise in Government Funding for Research and Development
5.2.2. Incidence of Pain
5.2.3. Patent Expiration of Novel Pain Management Drugs (Opioids)
5.2.4. Average Annual Spending on Pain Management Drugs
5.2.5. Awareness for Medications
5.2.6. Regulatory Approvals
5.2.7. Popularity of Generic Drug Class
5.2.8. Market Consolidation Activities
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market size (US$ million) Trend Analysis, 2019 to 2023
6.2. Current and Future Market Size (US$ million) and Forecast Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) Trend Analysis By Drug Class, 2019 to 2023
7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Drug Class, 2024 to 2034
7.3.1. Opioids
7.3.1.1. Hydrocodone
7.3.1.2. Oxycodone
7.3.1.3. Morphine
7.3.1.4. Fentanyl
7.3.1.5. Others
7.3.2. Non-opioids
7.3.2.1. Ibuprofen
7.3.2.2. Naproxen
7.3.2.3. Diclofenac
7.3.2.4. Acetaminophen
7.3.2.5. Lidocaine
7.3.2.6. Capsaicin
7.3.2.7. Corticosteroids
7.3.2.8. Prednisone
7.3.2.9. Dexamethasone
7.3.2.10. Others
7.4. Market Attractiveness Analysis By Drug Class
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Formulation
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Trend Analysis By Formulation, 2019 to 2023
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Formulation, 2024 to 2034
8.3.1. Creams and Ointments
8.3.2. Gels
8.3.3. Liquid/Oil
8.3.4. Patch
8.3.5. Sprays
8.3.6. Others
8.4. Market Attractiveness Analysis By Formulation
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Packaging Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) Trend Analysis By Packaging Type, 2019 to 2023
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Packaging Type, 2024 to 2034
9.3.1. Tubes
9.3.1.1. Creams and Ointments
9.3.1.2. Gels
9.3.2. Containers & Jars
9.3.2.1. Creams and Ointments
9.3.2.2. Gels
9.3.3. Aerosol Containers
9.3.3.1. Sprays
9.3.4. Dermal Patches
9.3.4.1. Patches
9.3.5. Roll On Bottles
9.3.5.1. Liquid/Oil
9.4. Market Attractiveness Analysis By Packaging Type
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) Trend Analysis By Distribution Channel, 2019 to 2023
10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Distribution Channel, 2024 to 2034
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Retail Pharmacy Stores
10.3.4. Drug Stores
10.3.5. Online Pharmacy Stores
10.3.6. Others
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Market : Cross Sectional Analysis - Drug Class Vs Distribution Channel
11.1. Historical Market Size (US$ million) By Drug Class Vs Distribution Channel, 2019 to 2023
11.2. Current and Future Market Size (US$ million) Analysis and Forecast by Drug Class Vs Distribution Channel, 2024 to 2034
11.2.1. Opioids
11.2.1.1. Hospitals
11.2.1.2. Clinics
11.2.1.3. Retail Pharmacy Stores
11.2.1.4. Drug Stores
11.2.1.5. Online Pharmacy Stores
11.2.1.6. Others
11.2.2. Non-Opioids
11.2.2.1. Hospitals
11.2.2.2. Clinics
11.2.2.3. Retail Pharmacy Stores
11.2.2.4. Drug Stores
11.2.2.5. Online Pharmacy Stores
11.2.2.6. Others
12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
12.1. Introduction
12.2. Historical Market Size (US$ million) Trend Analysis and By Region, 2019 to 2023
12.3. Current and Future Market Size (US$ million) Analysis and Forecast By Region, 2024 to 2034
12.3.1. North America
12.3.2. Latin America
12.3.3. East Asia
12.3.4. South Asia & Pacific
12.3.5. Western Europe
12.3.6. Eastern Europe
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis By Region
12.5. Key Market Trends, By Region
13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. United States
13.3.1.2. Canada
13.3.1.3. Mexico
13.3.2. By Drug Class
13.3.3. By Formulation
13.3.4. By Packaging Type
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Formulation
13.4.4. By Packaging Type
13.4.5. By Distribution Channel
13.5. Drivers and Restraints - Impact Analysis
13.6. Country Level Analysis & Forecast
13.6.1. United States Market Analysis
13.6.1.1. .Introduction
13.6.1.2. Market Analysis and Forecast by Market Taxonomy
13.6.1.2.1. By Drug Class
13.6.1.2.2. By Formulation
13.6.1.2.3. By Packaging Type
13.6.1.2.4. By Distribution Channel
13.6.2. Canada Market Analysis
13.6.2.1. Introduction
13.6.2.2. Market Analysis and Forecast by Market Taxonomy
13.6.2.2.1. By Drug Class
13.6.2.2.2. By Formulation
13.6.2.2.3. By Packaging Type
13.6.2.2.4. By Distribution Channel
13.6.3. Mexico Market Analysis
13.6.3.1. Introduction
13.6.3.2. Market Analysis and Forecast by Market Taxonomy
13.6.3.2.1. By Drug Class
13.6.3.2.2. By Formulation
13.6.3.2.3. By Packaging Type
13.6.3.2.4. By Distribution Channel
14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Chile
14.3.1.3. Rest of Latin America
14.3.2. By Drug Class
14.3.3. By Formulation
14.3.4. By Packaging Type
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Formulation
14.4.4. By Packaging Type
14.4.5. By Distribution Channel
14.5. Drivers and Restraints - Impact Analysis
14.6. Country Level Analysis & Forecast
14.6.1. Brazil Market Analysis
14.6.1.1. Introduction
14.6.1.2. Market Analysis and Forecast by Market Taxonomy
14.6.1.2.1. By Drug Class
14.6.1.2.2. By Formulation
14.6.1.2.3. By Packaging Type
14.6.1.2.4. By Distribution Channel
14.6.2. Chile Market Analysis
14.6.2.1. Introduction
14.6.2.2. Market Analysis and Forecast by Market Taxonomy
14.6.2.2.1. By Drug Class
14.6.2.2.2. By Formulation
14.6.2.2.3. By Packaging Type
14.6.2.2.4. By Distribution Channel
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Class
15.3.3. By Formulation
15.3.4. By Packaging Type
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Formulation
15.4.4. By Packaging Type
15.4.5. By Distribution Channel
15.5. Drivers and Restraints - Impact Analysis
15.6. Country Level Analysis & Forecast
15.6.1. China Market Analysis
15.6.1.1. Introduction
15.6.1.2. Market Analysis and Forecast by Market Taxonomy
15.6.1.2.1. By Drug Class
15.6.1.2.2. By Formulation
15.6.1.2.3. By Packaging Type
15.6.1.2.4. By Distribution Channel
15.6.2. Japan Market Analysis
15.6.2.1. Introduction
15.6.2.2. Market Analysis and Forecast by Market Taxonomy
15.6.2.2.1. By Drug Class
15.6.2.2.2. By Formulation
15.6.2.2.3. By Packaging Type
15.6.2.2.4. By Distribution Channel
15.6.3. South Korea Market Analysis
15.6.3.1. Introduction
15.6.3.2. Market Analysis and Forecast by Market Taxonomy
15.6.3.2.1. By Drug Class
15.6.3.2.2. By Formulation
15.6.3.2.3. By Packaging Type
15.6.3.2.4. By Distribution Channel
16. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ million) Trend Analysis & Forecast By Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Size (US$ million) Analysis and Forecast Analysis By Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. India
16.3.1.2. ASEAN Countries
16.3.1.3. Australia & New Zealand
16.3.1.4. Rest of South Asia & Pacific
16.3.2. By Drug Class
16.3.3. By Formulation
16.3.4. By Packaging Type
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Formulation
16.4.4. By Packaging Type
16.4.5. By Distribution Channel
16.5. Drivers and Restraints - Impact Analysis
16.6. Country Level Analysis & Forecast
16.6.1. India Market Analysis
16.6.1.1. Introduction
16.6.1.2. Market Analysis and Forecast by Market Taxonomy
16.6.1.2.1. By Drug Class
16.6.1.2.2. By Formulation
16.6.1.2.3. By Packaging Type
16.6.1.2.4. By Distribution Channel
16.6.2. ASEAN Countries Market Analysis
16.6.2.1. Introduction
16.6.2.2. Market Analysis and Forecast by Market Taxonomy
16.6.2.2.1. By Drug Class
16.6.2.2.2. By Formulation
16.6.2.2.3. By Packaging Type
16.6.2.2.4. By Distribution Channel
16.6.3. Australia & New Zealand Pain Relief Market Analysis
16.6.3.1. Introduction
16.6.3.2. Market Analysis and Forecast by Market Taxonomy
16.6.3.2.1. By Drug Class
16.6.3.2.2. By Formulation
16.6.3.2.3. By Packaging Type
16.6.3.2.4. By Distribution Channel
17. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Size (US$ million) Analysis and Forecast Analysis By Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. United Kingdom
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Nordic Countries
17.3.1.8. Rest of Western Europe
17.3.2. By Drug Class
17.3.3. By Formulation
17.3.4. By Packaging Type
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Formulation
17.4.4. By Packaging Type
17.4.5. By Distribution Channel
17.5. Drivers and Restraints - Impact Analysis
17.6. Country Level Analysis & Forecast
17.6.1. Germany Market Analysis
17.6.1.1. Introduction
17.6.1.2. Market Analysis and Forecast by Market Taxonomy
17.6.1.2.1. By Drug Class
17.6.1.2.2. By Formulation
17.6.1.2.3. By Packaging Type
17.6.1.2.4. By Distribution Channel
17.6.2. Italy Market Analysis
17.6.2.1. Introduction
17.6.2.2. Market Analysis and Forecast by Market Taxonomy
17.6.2.2.1. By Drug Class
17.6.2.2.2. By Formulation
17.6.2.2.3. By Packaging Type
17.6.2.2.4. By Distribution Channel
17.6.3. France Market Analysis
17.6.3.1. Introduction
17.6.3.2. Market Analysis and Forecast by Market Taxonomy
17.6.3.2.1. By Drug Class
17.6.3.2.2. By Formulation
17.6.3.2.3. By Packaging Type
17.6.3.2.4. By Distribution Channel
17.6.4. United Kingdom Market Analysis
17.6.4.1. Introduction
17.6.4.2. Market Analysis and Forecast by Market Taxonomy
17.6.4.2.1. By Drug Class
17.6.4.2.2. By Formulation
17.6.4.2.3. By Packaging Type
17.6.4.2.4. By Distribution Channel
17.6.5. Spain Market Analysis
17.6.5.1. Introduction
17.6.5.2. Market Analysis and Forecast by Market Taxonomy
17.6.5.2.1. By Drug Class
17.6.5.2.2. By Formulation
17.6.5.2.3. By Packaging Type
17.6.5.2.4. By Distribution Channel
17.6.6. BENELUX Market Analysis
17.6.6.1. Introduction
17.6.6.2. Market Analysis and Forecast by Market Taxonomy
17.6.6.2.1. By Drug Class
17.6.6.2.2. By Formulation
17.6.6.2.3. By Packaging Type
17.6.6.2.4. By Distribution Channel
17.6.7. Nordic Countries Market Analysis
17.6.7.1. Introduction
17.6.7.2. Market Analysis and Forecast by Market Taxonomy
17.6.7.2.1. By Drug Class
17.6.7.2.2. By Formulation
17.6.7.2.3. By Packaging Type
17.6.7.2.4. By Distribution Channel
18. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023
18.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034
18.3.1. By Country
18.3.1.1. Russia
18.3.1.2. Hungary
18.3.1.3. Poland
18.3.1.4. Rest of Eastern Europe
18.3.2. By Drug Class
18.3.3. By Formulation
18.3.4. By Packaging Type
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Drug Class
18.4.2. By Formulation
18.4.3. By Packaging Type
18.4.4. By Distribution Channel
18.5. Drivers and Restraints - Impact Analysis
18.6. Country Level Analysis & Forecast
18.6.1. Russia Market Analysis
18.6.1.1. Introduction
18.6.1.2. Market Analysis and Forecast by Market Taxonomy
18.6.1.2.1. By Drug Class
18.6.1.2.2. By Formulation
18.6.1.2.3. By Packaging Type
18.6.1.2.4. By Distribution Channel
18.6.2. Hungary Market Analysis
18.6.2.1. Introduction
18.6.2.2. Market Analysis and Forecast by Market Taxonomy
18.6.2.2.1. By Drug Class
18.6.2.2.2. By Formulation
18.6.2.2.3. By Packaging Type
18.6.2.2.4. By Distribution Channel
18.6.3. Poland Market Analysis
18.6.3.1. Introduction
18.6.3.2. Market Analysis and Forecast by Market Taxonomy
18.6.3.2.1. By Drug Class
18.6.3.2.2. By Formulation
18.6.3.2.3. By Packaging Type
18.6.3.2.4. By Distribution Channel
19. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
19.1. Introduction
19.2. Historical Market Size (US$ million) Trend Analysis & Forecast By Market Taxonomy, 2019 to 2023
19.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034
19.3.1. By Country
19.3.1.1. Saudi Arabia
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. Other African Union
19.3.1.5. Rest of Middle East & Africa
19.3.2. By Drug Class
19.3.3. By Formulation
19.3.4. By Packaging Type
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Class
19.4.3. By Formulation
19.4.4. By Packaging Type
19.4.5. By Distribution Channel
19.5. Drivers and Restraints - Impact Analysis
19.6. Country Level Analysis & Forecast
19.6.1. Saudi Arabia Market Analysis
19.6.1.1. Introduction
19.6.1.2. Market Analysis and Forecast by Market Taxonomy
19.6.1.2.1. By Drug Class
19.6.1.2.2. By Formulation
19.6.1.2.3. By Packaging Type
19.6.1.2.4. By Distribution Channel
19.6.2. Türkiye Market Analysis
19.6.2.1. Introduction
19.6.2.2. Market Analysis and Forecast by Market Taxonomy
19.6.2.2.1. By Drug Class
19.6.2.2.2. By Formulation
19.6.2.2.3. By Packaging Type
19.6.2.2.4. By Distribution Channel
19.6.3. South Africa Market Analysis
19.6.3.1. Introduction
19.6.3.2. Market Analysis and Forecast by Market Taxonomy
19.6.3.2.1. By Drug Class
19.6.3.2.2. By Formulation
19.6.3.2.3. By Packaging Type
19.6.3.2.4. By Distribution Channel
19.6.4. Other African Union Market Analysis
19.6.4.1. Introduction
19.6.4.2. Market Analysis and Forecast by Market Taxonomy
19.6.4.2.1. By Drug Class
19.6.4.2.2. By Formulation
19.6.4.2.3. By Packaging Type
19.6.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of top Players
20.3. Market Presence Analysis
20.3.1. By Regional Footprint of Players
20.3.2. Drug Class Footprint by Players
20.3.3. Channel Footprint by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Branding and Promotional Strategies, By Key Manufactures
21.4. Key Development Analysis
21.5. Competition Deep Dive
21.5.1. Johnson & Johnson
21.5.1.1. Overview
21.5.1.2. Drug Class Portfolio
21.5.1.3. Key Financials
21.5.1.4. Sales Footprint
21.5.1.5. SWOT Analysis
21.5.1.6. Strategy Overview
21.5.1.6.1. Marketing Strategies
21.5.1.6.2. Channel Strategies
21.5.1.6.3. Drug Class Strategies
21.5.2. Pfizer Inc.
21.5.3. Novartis AG
21.5.4. Glaxosmithkline Plc (GSK)
21.5.5. Sanofi
21.5.6. Bayer AG
21.5.7. Abbott Laboratories
21.5.8. Reckitt Benckiser Group Plc.
21.5.9. Teva Pharmaceutical Industries Ltd.
21.5.10. Thermo Fisher Scientific, Inc.
21.5.11. Haleon Group of Companies
21.5.12. Procter & Gamble
21.5.13. Sun Pharmaceutical Industries Ltd.
21.5.14. Amneal Pharmaceuticals LLC.
21.5.15. Cipla Limited
21.5.16. Purdue Pharmaceuticals L.P.
21.5.17. Hisamitsu Pharmaceutical Co., Inc.
21.5.18. Endo Pharmaceuticals, Inc.
21.5.19. Mallinckrodt Pharmaceuticals
21.5.20. Pure Source LLC
21.5.21. Teikoku Pharma
21.5.22. Himalaya Wellness Company
21.5.23. Troy Healthcare LLC
21.5.24. Advacare Pharma
21.5.25. Exzell Pharma
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Topical Pain Relief Market
